Home › FDA Approves Mercks Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
 

Keywords :   


FDA Approves Mercks Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)

2016-02-04 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. First and Only Intravenous NK1 Receptor Antagonist Approved in the U.S. for Use in MEC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND (fosaprepitant dimeglumine) for injection, Mercks substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines, for the prevention of delayed nausea and vomiting in adults receiving initial and repeat courses of moderately emetogenic chemotherapy (MEC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: combination agents receiving adults

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.05Qantas agrees payouts over 'ghost flights'
06.05The rise of Sweden's super rich
06.05Eurotunnel says no queues with new travel system
05.05ELF Beauty Teams with Billie Jean King to Change the Board Game to Support Inclusivity
05.05Target Faces Lawsuit Over Sunscreen Coral Bleaching Claims
05.05Goops Latest Launch & Hain Celestial Streamlines Portfolio
05.05The Summer of Sister Golden Hair
05.05Persil Laundry Detergent Rebrands
More »